Elanco Animal Health (ELAN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ELAN Stock Forecast


Elanco Animal Health stock forecast is as follows: an average price target of $26.50 (represents a 110.99% upside from ELAN’s last price of $12.56) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

ELAN Price Target


The average price target for Elanco Animal Health (ELAN) is $26.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $16.00. This represents a potential 110.99% upside from ELAN's last price of $12.56.

ELAN Analyst Ratings


Buy

According to 5 Wall Street analysts, Elanco Animal Health's rating consensus is 'Buy'. The analyst rating breakdown for ELAN stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

Elanco Animal Health Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2024Balaji PrasadBarclays$22.00$14.0756.36%75.16%
Jul 01, 2024David WestenbergPiper Sandler$16.00$14.4310.88%27.39%
May 13, 2024David WestenbergPiper Sandler$19.00$17.0011.76%51.27%
Mar 12, 2024David WestenbergPiper Sandler$18.00$15.7714.14%43.31%
Jan 05, 2024Jonathan BlockStifel Nicolaus$20.00$15.4529.45%59.24%
Sep 12, 2022-Barclays$18.00$15.0020.00%43.31%
Aug 16, 2022David WestenbergPiper Sandler$21.00$19.0810.06%67.20%
Jul 18, 2022-J.P. Morgan$32.00$20.1458.89%154.78%
Jun 24, 2022-Stifel Nicolaus$22.00$19.9410.33%75.16%
May 19, 2022-Goldman Sachs$32.00$23.3537.04%154.78%
Row per page
Go to

The latest Elanco Animal Health stock forecast, released on Sep 23, 2024 by Balaji Prasad from Barclays, set a price target of $22.00, which represents a 56.36% increase from the stock price at the time of the forecast ($14.07), and a 75.16% increase from ELAN last price ($12.56).

Elanco Animal Health Price Target by Period


1M3M12M
# Anlaysts-15
Avg Price Target-$22.00$19.00
Last Closing Price$12.56$12.56$12.56
Upside/Downside-100.00%75.16%51.27%

In the current month, the average price target of Elanco Animal Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Elanco Animal Health's last price of $12.56. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2024Morgan StanleyBuyBuyHold
Sep 23, 2024BarclaysOverweightOverweightHold
Sep 20, 2024Piper SandlerNeutralNeutralHold
Sep 19, 2024Piper SandlerBuyBuyHold
Sep 19, 2024Morgan StanleyUnderperformUnderperformHold
Sep 19, 2024Morgan StanleyOverweightEqual-WeightDowngrade
Jul 01, 2024Piper SandlerNeutralNeutralHold
May 13, 2024Piper SandlerNeutralNeutralHold
May 09, 2024Bank of America SecuritiesBuyBuyHold
May 09, 2024BarclaysOverweightOverweightHold
Row per page
Go to

Elanco Animal Health's last stock rating was published by Morgan Stanley on Oct 28, 2024. The company gave ELAN a "Buy" rating, the same as its previous rate.

Elanco Animal Health Financial Forecast


Elanco Animal Health Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$1.07B$1.06B$1.26B$988.00M$1.03B$1.18B$1.23B$1.11B$1.13B$1.28B$1.24B$1.14B$889.60M$586.30M$657.70M$787.00M$771.30M
Avg Forecast$1.10B$1.12B$1.24B$1.28B$1.06B$1.09B$1.18B$1.22B$1.01B$1.04B$1.15B$1.19B$1.00B$1.04B$1.04B$1.19B$980.94M$1.03B$1.18B$1.22B$1.10B$1.08B$1.24B$1.16B$1.05B$913.80M$575.44M$721.62M$790.45M$764.69M
High Forecast$1.10B$1.12B$1.24B$1.28B$1.06B$1.09B$1.18B$1.22B$1.01B$1.05B$1.15B$1.19B$1.01B$1.04B$1.04B$1.19B$980.94M$1.03B$1.18B$1.22B$1.10B$1.08B$1.24B$1.16B$1.05B$913.80M$575.44M$721.62M$790.45M$764.69M
Low Forecast$1.10B$1.12B$1.24B$1.28B$1.06B$1.09B$1.18B$1.22B$1.01B$1.04B$1.15B$1.18B$988.87M$1.04B$1.04B$1.19B$980.94M$1.03B$1.18B$1.22B$1.10B$1.08B$1.24B$1.16B$1.05B$913.80M$575.44M$721.62M$790.45M$764.69M
# Analysts334545223734756322223456999955
Surprise %-------------1.03%1.02%1.05%1.01%1.00%1.00%1.01%1.01%1.05%1.03%1.07%1.08%0.97%1.02%0.91%1.00%1.01%

Elanco Animal Health's average Quarter revenue forecast for Dec 23 based on 7 analysts is $1.00B, with a low forecast of $988.87M, and a high forecast of $1.01B. ELAN's average Quarter revenue forecast represents a -6.21% decrease compared to the company's last Quarter revenue of $1.07B (Sep 23).

Elanco Animal Health EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts334545223734756322223456999955
EBITDA-------------$42.00M$166.00M$346.00M$136.00M$211.00M$268.00M$345.00M$108.00M$100.00M$-6.00M$183.00M$-35.50M$-28.60M$28.60M$30.20M$97.80M$84.90M
Avg Forecast$201.39M$204.36M$226.77M$233.38M$193.80M$197.79M$214.84M$221.96M$184.42M$188.87M$209.23M$351.45M$182.55M$189.47M$189.12M$319.50M$90.85M$188.14M$214.61M$290.46M$201.16M$197.23M$226.36M$78.77M$192.24M$166.54M$104.88M$39.64M$144.06M$139.37M
High Forecast$201.39M$204.36M$226.77M$233.38M$193.80M$197.79M$214.84M$221.96M$184.42M$190.70M$209.23M$421.74M$184.43M$189.66M$189.12M$383.40M$109.02M$188.14M$214.61M$348.55M$201.16M$197.23M$226.36M$94.52M$192.24M$166.54M$104.88M$47.56M$144.06M$139.37M
Low Forecast$201.39M$204.36M$226.77M$233.38M$193.80M$197.79M$214.84M$221.96M$184.42M$188.87M$209.23M$281.16M$180.23M$189.28M$189.12M$255.60M$72.68M$188.14M$214.61M$232.37M$201.16M$197.23M$226.36M$63.02M$192.24M$166.54M$104.88M$31.71M$144.06M$139.37M
Surprise %-------------0.22%0.88%1.08%1.50%1.12%1.25%1.19%0.54%0.51%-0.03%2.32%-0.18%-0.17%0.27%0.76%0.68%0.61%

7 analysts predict ELAN's average Quarter EBITDA for Dec 23 to be $182.55M, with a high of $184.43M and a low of $180.23M. This is 334.65% upper than Elanco Animal Health's previous annual EBITDA (Sep 23) of $42.00M.

Elanco Animal Health Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts334545223734756322223456999955
Net Income-------------$-1.10B$-97.00M$103.00M$-54.00M$-49.00M$-22.00M$48.00M$-97.00M$-104.00M$-210.00M$-61.00M$-322.80M$-135.00M$-53.20M$-49.10M$-9.50M$10.00M
Avg Forecast$102.87M$84.09M$153.13M$179.96M$89.03M$75.77M$141.65M$158.83M$79.97M$60.42M$118.45M$56.42M$51.66M$61.59M$23.26M$51.29M$-81.59M$78.39M$124.66M$46.63M$83.20M$81.70M$132.68M$-26.26M$48.79M$59.80M$18.46M$-64.44M$112.45M$126.68M
High Forecast$102.87M$84.09M$153.13M$179.96M$89.03M$75.77M$141.65M$158.83M$79.97M$65.45M$118.53M$67.70M$67.16M$62.99M$23.26M$61.55M$-65.28M$78.39M$124.66M$55.95M$83.20M$81.70M$132.68M$-21.01M$48.79M$59.80M$18.46M$-51.55M$112.45M$126.68M
Low Forecast$102.87M$84.09M$153.13M$179.96M$89.03M$75.77M$141.65M$158.83M$79.97M$50.35M$118.38M$45.14M$41.33M$60.20M$23.26M$41.03M$-97.91M$78.39M$124.66M$37.30M$83.20M$81.70M$132.68M$-31.51M$48.79M$59.80M$18.46M$-77.33M$112.45M$126.68M
Surprise %--------------17.79%-4.17%2.01%0.66%-0.63%-0.18%1.03%-1.17%-1.27%-1.58%2.32%-6.62%-2.26%-2.88%0.76%-0.08%0.08%

Elanco Animal Health's average Quarter net income forecast for Jun 23 is $23.26M, with a range of $23.26M to $23.26M. ELAN's average Quarter net income forecast represents a -77.42% decrease compared to the company's last Quarter net income of $103.00M (Mar 23).

Elanco Animal Health SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts334545223734756322223456999955
SG&A-------------$313.00M$353.00M$327.00M$303.00M$298.00M$343.00M$320.00M$329.00M$342.00M$385.00M$348.00M$374.10M$277.70M$162.80M$364.00M$237.30M$243.00M
Avg Forecast$314.73M$319.38M$354.39M$364.72M$302.87M$309.11M$335.75M$346.87M$288.21M$295.16M$326.97M$376.14M$285.29M$296.10M$295.55M$341.94M$276.75M$294.02M$335.38M$310.86M$314.37M$308.22M$353.76M$149.79M$300.43M$260.27M$163.90M$477.75M$225.14M$217.80M
High Forecast$314.73M$319.38M$354.39M$364.72M$302.87M$309.11M$335.75M$346.87M$288.21M$298.03M$326.97M$451.36M$288.22M$296.39M$295.55M$410.33M$332.10M$294.02M$335.38M$373.03M$314.37M$308.22M$353.76M$179.75M$300.43M$260.27M$163.90M$573.30M$225.14M$217.80M
Low Forecast$314.73M$319.38M$354.39M$364.72M$302.87M$309.11M$335.75M$346.87M$288.21M$295.16M$326.97M$300.91M$281.66M$295.81M$295.55M$273.55M$221.40M$294.02M$335.38M$248.69M$314.37M$308.22M$353.76M$119.83M$300.43M$260.27M$163.90M$382.20M$225.14M$217.80M
Surprise %-------------1.06%1.19%0.96%1.09%1.01%1.02%1.03%1.05%1.11%1.09%2.32%1.25%1.07%0.99%0.76%1.05%1.12%

Elanco Animal Health's average Quarter SG&A projection for Dec 23 is $285.29M, based on 7 Wall Street analysts, with a range of $281.66M to $288.22M. The forecast indicates a -8.85% fall compared to ELAN last annual SG&A of $313.00M (Sep 23).

Elanco Animal Health EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts334545223734756322223456999955
EPS-------------$-2.22$-0.20$0.21$-0.11$-0.10$-0.04$0.10$-0.20$-0.21$-0.43$-0.12$-0.66$-0.29$-0.13$-0.12$-0.03$0.03
Avg Forecast$0.21$0.17$0.31$0.36$0.18$0.15$0.29$0.32$0.16$0.12$0.24$0.27$0.10$0.12$0.05$0.29$0.13$0.16$0.25$0.35$0.17$0.17$0.27$0.23$0.10$0.12$0.04$0.24$0.23$0.26
High Forecast$0.21$0.17$0.31$0.36$0.18$0.15$0.29$0.32$0.16$0.13$0.24$0.28$0.14$0.13$0.05$0.29$0.13$0.16$0.25$0.35$0.17$0.17$0.27$0.23$0.10$0.12$0.04$0.24$0.23$0.26
Low Forecast$0.21$0.17$0.31$0.36$0.18$0.15$0.29$0.32$0.16$0.10$0.24$0.27$0.08$0.12$0.05$0.29$0.13$0.16$0.25$0.35$0.17$0.17$0.27$0.23$0.10$0.12$0.04$0.24$0.23$0.26
Surprise %--------------17.81%-4.25%0.74%-0.86%-0.63%-0.18%0.28%-1.19%-1.27%-1.60%-0.53%-6.68%-2.40%-3.48%-0.51%-0.13%0.12%

According to 6 Wall Street analysts, Elanco Animal Health's projected average Quarter EPS for Jun 23 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a -77.59% decrease compared to ELAN previous annual EPS of $0.21 (Mar 23).

Elanco Animal Health Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ESPREsperion Therapeutics$2.00$16.00700.00%Buy
IRWDIronwood Pharmaceuticals$4.19$11.67178.52%Buy
PCRXPacira BioSciences$16.45$40.00143.16%Hold
ELANElanco Animal Health$12.56$26.50110.99%Buy
CTLTCatalent$58.69$76.4030.18%Hold
ALKSAlkermes$26.59$34.3829.30%Hold
COLLCollegium Pharmaceutical$32.72$41.5026.83%Buy
LNTHLantheus$115.45$146.2526.68%Buy
VTRSViatris$11.45$13.7520.09%Hold
PBHPrestige Consumer Healthcare$73.79$82.0011.13%Buy
ITCIIntra-Cellular Therapies$86.17$94.509.67%Buy
TEVATeva Pharmaceutical Industries$18.64$20.007.30%Buy
DCPHDeciphera Pharmaceuticals$25.59$26.322.85%Hold
HLNHaleon$9.76$9.15-6.25%Buy
PAHCPhibro Animal Health$22.37$18.67-16.54%Buy

ELAN Forecast FAQ


Yes, according to 5 Wall Street analysts, Elanco Animal Health (ELAN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of ELAN's total ratings.

Elanco Animal Health (ELAN) average price target is $26.5 with a range of $16 to $37, implying a 110.99% from its last price of $12.56. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ELAN stock, the company can go up by 110.99% (from the last price of $12.56 to the average price target of $26.5), up by 194.59% based on the highest stock price target, and up by 27.39% based on the lowest stock price target.

ELAN's average twelve months analyst stock price target of $26.5 supports the claim that Elanco Animal Health can reach $20 in the near future.

Elanco Animal Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.55B (high $4.55B, low $4.55B), average EBITDA is $828.39M (high $828.39M, low $828.39M), average net income is $465.27M (high $465.27M, low $465.27M), average SG&A $1.29B (high $1.29B, low $1.29B), and average EPS is $0.941 (high $0.941, low $0.941). ELAN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $4.75B (high $4.75B, low $4.75B), average EBITDA is $865.9M (high $865.9M, low $865.9M), average net income is $520.05M (high $520.05M, low $520.05M), average SG&A $1.35B (high $1.35B, low $1.35B), and average EPS is $1.05 (high $1.05, low $1.05).

Based on Elanco Animal Health's last annual report (Dec 2023), the company's revenue was $4.42B, beating the average analysts forecast of $4.27B by 3.39%. Apple's EBITDA was $326M, missing the average prediction of $880.64M by -62.98%. The company's net income was $-1.231B, missing the average estimation of $187.81M by -755.46%. Apple's SG&A was $1.28B, beating the average forecast of $1.22B by 5.42%. Lastly, the company's EPS was $-2.5, missing the average prediction of $0.561 by -545.42%. In terms of the last quarterly report (Sep 2023), Elanco Animal Health's revenue was $1.07B, beating the average analysts' forecast of $1.04B by 2.73%. The company's EBITDA was $42M, missing the average prediction of $189.47M by -77.83%. Elanco Animal Health's net income was $-1.096B, missing the average estimation of $61.59M by -1879.45%. The company's SG&A was $313M, beating the average forecast of $296.1M by 5.71%. Lastly, the company's EPS was $-2.22, missing the average prediction of $0.125 by -1881.27%